Cheshire-headquartered biotech firm Centauri Therapeutics has obtained $5.1m (£3.8m) in funding to assist the event of its lead compound.
Primarily based in Alderley Park, Centauri specialises in immunotherapy drug discovery and is at the moment engaged on the event of its ABX-01 programme, a broad-spectrum antimicrobial chosen to fight clinically prevalent drug-resistant micro organism.
In assist of this, the Combating Antibiotic-Resistant Micro organism Biopharmaceutical Accelerator (CARB-X) has supplied the brand new funding.
“The unwavering scientific and monetary assist from CARB-X has supplied stability to Centauri as an organization, expanded understanding of our Alphamer platform, and enabled us to progress the ABX-01 programme from discovery, by early growth, and is now offering a clean and steady path in direction of First in Human scientific research,” stated Dr. Jennifer Schneider, chief govt of Centauri Therapeutics.
“We’re grateful for CARB-X and their continued engagement and confidence, which has allowed us to maneuver a step nearer to delivering a a lot wanted therapeutic for critical, drug-resistant Gram-negative infections, even in probably the most clinically weak sufferers.”
The newest spherical of funding brings the overall quantity supplied to Centauri by CARB-X to $12.3m (£9.2m).
Dr. Erin Duffy, chief of analysis and growth at CARB-X, commented: “We’ve got been proud to assist Centauri, starting with answering key questions on the strategy and persevering with with the drug discovery that has led to the lead asset of ABX-01 and its development in direction of constructing a file to assist its development into first in human scientific trials.”
Register for Free
Bookmark your favourite posts, get day by day updates, and luxuriate in an ad-reduced expertise.
Have already got an account? Log in
